State Street
AARD

State Street’s Aardvark Therapeutics AARD Stock Holding History

State Street’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$751K Buy
199,322
+41,082
+26% +$426K ﹤0.01% 3557
2025
Q4 		$2.08M Buy
158,240
+65,235
+70% +$814K ﹤0.01% 3329
2025
Q3 		$1.24M Buy
93,005
+55,693
+149% +$628K ﹤0.01% 3460
2025
Q2 		$504K Buy
+37,312
New +$384K ﹤0.01% 3618

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street's AARD Position: Q1 2026 in Review

State Street increased its Aardvark Therapeutics (AARD) stake by 26% in Q1 2026, buying an estimated $426K and bringing the position to 199,322 shares worth $751K. The position accounts for ﹤0.01% of the portfolio, ranked #3557.

State Street first reported a position in AARD in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.08M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • State Street held 199,322 shares of Aardvark Therapeutics worth $751K as of Q1 2026.
  • State Street bought 41,082 Aardvark Therapeutics shares in Q1 2026, an estimated $426K.
  • Aardvark Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3557 holding.
  • State Street first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • State Street's Aardvark Therapeutics position peaked at $2.08M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.